UK & Europe
The United Kingdom and continental Europe.
Cell & Gene Therapy
Taranis Capital and EEC Partner to Build Next-Generation Data Centres
Taranis Capital and Emaar Executive Company partner to develop carrier-neutral data centres across Saudi Arabia, supporting rising AI and cloud demand under Vision 2030
Taranis Capital Limited (“Taranis”), a DFSA-regulated investment firm based in Dubai International Financial Centre (DIFC), has signed a Memorandum of Understanding (MOU) with Emaar Executive Company (EEC) to develop, construct, and operate a portfolio of next-generation, carr
Genomics
Inside the UK's £650m bet on genomic medicine
With Genomics England's newborn screening trial now enrolling, the Department of Health has made its most explicit commitment yet to whole-genome sequencing as frontline NHS infrastructure.
The UK government has quietly positioned itself at the front of a race few of its peers are even running.
Medical Devices
Digital Health
Diagnostics
Philips wins two ITEA 2026 awards for AI-enabled healthcare projects
Philips-led consortia SYMPHONY and AI FORSchung received ITEA Awards of Excellence for connected clinical AI and fibre-optic data compression.
Philips-led consortia SYMPHONY and AI FORSchung received ITEA Awards of Excellence for connected clinical AI and fibre-optic data compression.
Biologics
Pharmaceuticals
Roche's Ocrevus gets CHMP backing for paediatric MS
The EMA's medicines committee has recommended ocrelizumab for children aged 10 and over with relapsing MS, following Phase III superiority data over fingolimod.
The EMA's medicines committee has recommended ocrelizumab for children aged 10 and over with relapsing MS, following Phase III superiority data over fingolimod.
Biologics
Pharmaceuticals
J&J's teclistamab wins CHMP backing for second-line myeloma use
The EMA's medicines committee has recommended expanding teclistamab's label to relapsed/refractory myeloma patients after just one prior therapy.
The EMA's medicines committee has recommended expanding teclistamab's label to relapsed/refractory myeloma patients after just one prior therapy.
Biologics
Pharmaceuticals
Regulatory Science
Novo Nordisk's Sogroya wins CHMP backing for idiopathic short stature
A positive EMA committee opinion positions somapacitan as the first growth hormone treatment recommended for ISS in the EU, pending European Commission sign-off.
A positive EMA committee opinion positions somapacitan as the first growth hormone treatment recommended for ISS in the EU, pending European Commission sign-off.
Biologics
Pharmaceuticals
Novartis secukinumab gets positive CHMP opinion for PMR
The EMA's advisory committee has backed Cosentyx as the first IL-17A inhibitor for polymyalgia rheumatica in Europe, pending European Commission sign-off.
The EMA's advisory committee has backed Cosentyx as the first IL-17A inhibitor for polymyalgia rheumatica in Europe, pending European Commission sign-off.
Pharmaceuticals
Biologics
Regulatory Science
Zealand Pharma gets CHMP nod for glepaglutide in short bowel syndrome
The EMA's CHMP has recommended Zeydovio for short bowel syndrome, the first major European advance in the indication for over a decade.
The EMA's CHMP has recommended Zeydovio for short bowel syndrome, the first major European advance in the indication for over a decade.
Biologics
Pharmaceuticals
Bavarian Nordic appoints Tarja Stenvall as CEO from October
The Danish vaccine company has named Sanofi and AstraZeneca veteran Tarja Stenvall as its new chief executive, effective 15 October 2026.
The Danish vaccine company has named Sanofi and AstraZeneca veteran Tarja Stenvall as its new chief executive, effective 15 October 2026.
Biologics
Pharmaceuticals
Novo Nordisk wins CHMP nod for denecimig in haemophilia A
The EMA advisory committee recommended EU approval of FREHEMGO, a bispecific antibody offering monthly, fortnightly or weekly dosing in a pre-filled pen.
The EMA advisory committee recommended EU approval of FREHEMGO, a bispecific antibody offering monthly, fortnightly or weekly dosing in a pre-filled pen.
Biologics
Pharmaceuticals
Roche's Lunsumio plus lenalidomide meets Phase III PFS endpoint in FL
Roche's CELESTIMO study showed mosunetuzumab plus lenalidomide significantly improved progression-free survival in relapsed or refractory follicular lymphoma.
Roche's CELESTIMO study showed mosunetuzumab plus lenalidomide significantly improved progression-free survival in relapsed or refractory follicular lymphoma.
Medical Devices
Biologics
Pharmaceuticals
EIB and Angelini Ventures hit €48.5m deployed under €150m facility
The EIB-Angelini Ventures co-investment partnership has backed five European life sciences companies in under a year, with €100m expected deployed by early 2027.
The EIB-Angelini Ventures co-investment partnership has backed five European life sciences companies in under a year, with €100m expected deployed by early 2027.
Pharmaceuticals
Regulatory Science
Elevar Therapeutics files EMA application for lirafugratinib in CCA
Elevar has submitted a marketing authorisation application to the EMA for its selective FGFR2 inhibitor, backed by a 46.5% response rate in second-line
Elevar has submitted a marketing authorisation application to the EMA for its selective FGFR2 inhibitor, backed by a 46.5% response rate in second-line
Pharmaceuticals
Diagnostics
Cell & Gene Therapy
KORTUC hits 184-patient enrolment in registrational breast cancer trial
The Palo Alto radiosensitizer biotech said its UK-led breast cancer study is now moving toward a 2027 efficacy readout, as two further cancer trials
The Palo Alto radiosensitizer biotech said its UK-led breast cancer study is now moving toward a 2027 efficacy readout, as two further cancer trials
Biologics
Pharmaceuticals
One04 Therapeutics launches on Phase 1 data for Factor H candidate
The Freiburg biotech launched publicly on encouraging CPV-104 Phase 1 interim results in C3G, with two new trials targeting kidney disease and dry AMD
The Freiburg biotech launched publicly on encouraging CPV-104 Phase 1 interim results in C3G, with two new trials targeting kidney disease and dry AMD
Pharmaceuticals
Diagnostics
Agomab reports positive Phase 1 data for inhaled IPF drug AGMB-447
Agomab's lung-restricted ALK5 inhibitor showed favourable safety and proof-of-mechanism in IPF patients; a Phase 2 study is set to begin before
Agomab's lung-restricted ALK5 inhibitor showed favourable safety and proof-of-mechanism in IPF patients; a Phase 2 study is set to begin before
Biologics
Pharmaceuticals
Immunocore completes TEBE-AM enrolment as tebentafusp Phase 3 matures
Immunocore has enrolled 540 patients in its registrational TEBE-AM trial, with topline overall survival data expected as early as end of 2026.
Immunocore has enrolled 540 patients in its registrational TEBE-AM trial, with topline overall survival data expected as early as end of 2026.
Pharmaceuticals
Diagnostics
Persica bolsters PP353 rationale with disc microbiology review
A new methodological scoping review by Persica Pharmaceuticals argues that low assay sensitivity explains conflicting findings on bacterial presence in spinal discs.
A new methodological scoping review by Persica Pharmaceuticals argues that low assay sensitivity explains conflicting findings on bacterial presence in spinal discs.
Medical Devices
SS Innovations reports 14,000+ procedures and telesurgery record
SS Innovations says its SSi Mantra system has surpassed 14,100 cumulative procedures and set a new longest-distance telesurgery record spanning 13,600 miles.
SS Innovations says its SSi Mantra system has surpassed 14,100 cumulative procedures and set a new longest-distance telesurgery record spanning 13,600 miles.